2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

bacterial wound infections

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Biochemical Assay Reagents

10

Peptides

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4744
    LL-37 amide
    2 Publications Verification

    		 Formyl Peptide Receptor (FPR) Bacterial Infection Cancer
    LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
    LL-37 amide
  • HY-B0614A
    Mafenide Acetate

    		Bacterial Fungal Infection
    Mafenide Acetate is a potent sulfonamide antimicrobial agent. Mafenide Acetate exhibits antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa. Mafenide Acetate also exhibits antifungal activity against filamentous fungi (e.g., Lichtheimia and Aspergillus flavus). Mafenide Acetate can be used in the research of skin grafts on burn wounds, post-traumatic invasive fungal infections, and bacterially contaminated wounds .
    Mafenide Acetate
  • HY-P5557
    TP4 (Nile tilapia piscidin)

    		Bacterial Necroptosis Infection Inflammation/Immunology
    TP4 (Nile tilapia piscidin) is an orally active amphipathic α-helical cationic antimicrobial peptide. TP4 (Nile tilapia piscidin) exerts broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria by disrupting cell membrane structures, and also exhibits certain hemolytic activity. TP4 (Nile tilapia piscidin) regulates the innate immune system and enhances the expression of lysozymes, cytokines and antioxidant enzymes to resist bacterial infection. TP4 (Nile tilapia piscidin) also stimulates the proliferation of keratinocytes and fibroblasts, and significantly promotes the healing of wounds infected with MRSA. TP4 (Nile tilapia piscidin) can be used in research related to bacterial infection, peritonitis, wound healing and other fields .
    TP4 (Nile tilapia piscidin)
  • HY-148775A
    mPEG-PLGA (21500-26500)

    		Biochemical Assay Reagents Infection Neurological Disease Cancer
    MPEG-PLGA (21500-26500) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. MPEG-PLGA (21500-26500) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. MPEG-PLGA (21500-26500) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. MPEG-PLGA (21500-26500) can be used for studies related to bacterial wound infections and glioblastoma .
    mPEG-PLGA (21500-26500)
  • HY-P4744A
    LL-37 amide TFA
    2 Publications Verification

    		 Formyl Peptide Receptor (FPR) Bacterial Infection Cancer
    LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
    LL-37 amide TFA
  • HY-148775B
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60)
    1 Publications Verification

    		 Biochemical Assay Reagents Infection Neurological Disease Cancer
    PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) can be used for studies related to bacterial wound infections and glioblastoma .
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60)
  • HY-P5545
    Lynronne-1

    		Bacterial Infection
    Lynronne-1 is an antimicrobial peptide. Lynronne-1 is active against Gram-positive bacterials, including MDR strains (MIC: 8-32 μg/mL for methicillin-resistant MRSA strains). Lynronne-1 reduces the bacterial load in MRSA infected wound murine model. Lynronne-1 is also effective against P. aeruginosa infection .
    Lynronne-1
  • HY-148775
    PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)

    		Biochemical Assay Reagents Infection Neurological Disease Cancer
    PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can be used for studies related to bacterial wound infections and glioblastoma .
    PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)
  • HY-P11165
    DRGN-1

    		Bacterial Infection
    DRGN-1 is an antimicrobial peptide. DRGN-1 exhibits potent antimicrobial and anti-biofilm activities, inhibiting both Gram-negative and Gram-positive bacteria, with an EC50 range of 0.50-4.62 μM. DRGN-1 exerts its antimicrobial effect by disrupting bacterial membrane permeability and slightly depolarizing the membrane potential. DRGN-1 inhibits the formation of biofilms of single bacterial species and mixed species of Pseudomonas aeruginosa and Staphylococcus aureus. DRGN-1 can significantly promote the healing of uninfected and mixed biofilm-infected mouse wounds. DRGN-1 can be used for the study of infections .
    DRGN-1
  • HY-P11004
    A3-APO

    		Bacterial Antibiotic Infection
    A3-APO is an antimicrobial peptide. A3-APO has a significant antimicrobial activity by a dual mode of action with both membrane disintegration and intracellular target inhibition. A3-APO can deactivate bacterial toxins and increase the expression of anti-inflammatory cytokines (such as IL-4 and IL-10), without antimicrobial resistance. A3-APO accelerates burn wounds healing in mice infection model of Acinetobacter baumannii and Staphylococcus aureus .
    A3-APO
  • HY-B0614AR
    Mafenide Acetate (Standard)

    		Reference Standards Bacterial Fungal Infection
    Mafenide (Acetate) (Standard) is the analytical standard of Mafenide Acetate (HY-B0614A). This product is intended for research and analytical applications. Mafenide Acetate is a potent sulfonamide antimicrobial agent. Mafenide Acetate exhibits antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa. Mafenide Acetate also exhibits antifungal activity against filamentous fungi (e.g., Lichtheimia and Aspergillus flavus). Mafenide Acetate can be used in the research of skin grafts on burn wounds, post-traumatic invasive fungal infections, and bacterially contaminated wounds .
    Mafenide Acetate (Standard)
  • HY-162818
    Antibacterial agent 237

    		Bacterial Reactive Oxygen Species (ROS) Infection
    Antibacterial agent 237 (compound Ru-8) is a bacteriostatic agent for Staphylococcus aureus, with MIC of 0.78-1.56 μg/mL. Antibacterial agent 237 destroys bacterial cell membranes, changes their permeability, and induces bacteria to produce Reactive Oxygen Species, leading to bacterial death without causing drug resistance. Antibacterial agent 237 has low hemolytic toxicity to rabbit red blood cells and Raw 264.7 cells, and has significant antibacterial effects against Staphylococcus aureus in mouse skin wound infection models and Bacillus major larvae infection models .
    Antibacterial agent 237
  • HY-174985
    Anti-MRSA agent 32

    		Bacterial Infection
    Anti-MRSA agent 32 (Compound 26) is an orally active and selective SaClpP (Staphylococcus aureus ClpP protease) activator with an EC50 value of 0.98 μM. Anti-MRSA agent 32 activates SaClpP to abnormally degrade bacterial proteins, inhibiting the proliferation of Staphylococcus aureus. Anti-MRSA agent 32 promotes wound healing in a murine skin infection model. Anti-MRSA agent 32 is promising for research of infectious diseases such as methicillin-resistant Staphylococcus aureus (MRSA) infections .
    Anti-MRSA agent 32
  • HY-168204
    3-Acetyl-28-N-(3-guanidinobutoxy)-oleanolic acid

    		Bacterial Fungal Infection
    3-Acetyl-28-N–(3–guanidinobutoxy)-oleanolic acid (compound J1) is a potent antimicrobial agent. 3-Acetyl-28-N–(3–guanidinobutoxy)-oleanolic acid shows anti-gram-positive bacteria and fungi activity. 3-Acetyl-28-N–(3–guanidinobutoxy)-oleanolic acid can be used as antibiotic adjuvants. 3-Acetyl-28-N–(3–guanidinobutoxy)-oleanolic disrupts the bacterial cell membrane, inserts into the DNA, and binds to DNA gyrase. 3-Acetyl-28-N–(3–guanidinobutoxy)-oleanolic reduces microbial count in a mouse MRSA skin infection model and accelerates wound healing .
    3-Acetyl-28-N-(3-guanidinobutoxy)-oleanolic acid
  • HY-P11616
    WK2

    		Bacterial TNF Receptor Infection
    WK2 is an antibacterial agent. WK2 reduces serum TNF-α production induced by Bacterial infection. WK2 reduces wound size and promotes tissue repair in a skin wound infection model. WK2 exerts anti-inflammatory effects in a pneumonia model. WK2 can be used for research on infectious diseases such as pneumonia caused by bacterial infection .
    WK2
  • HY-182027
    Antibacterial agent 330

    		Bacterial Reactive Oxygen Species (ROS) Lactate Dehydrogenase DNA/RNA Synthesis Infection
    Antibacterial agent 330 is an antibacterial agent. Antibacterial agent 330 triggers ROS accumulation, forms DNA supramolecular complex by intercalation to block DNA replication and inhibits LDH to
    disturb metabolism, and further prompts bacterial cell rupture to induce the leakage of intracellular content, ultimately causing bacterial death. Antibacterial agent 330 displays antibacterial activity and promotes wound healing in both G. Mellonella larval and murine wound infection models. Antibacterial agent 330 can be used for the research of bacterial infections .
    Antibacterial agent 330
  • HY-P11592
    KIKIKPWWWPKIKIK-NH2

    		Bacterial Infection
    KIKIKPWWWPKIKIK-NH2 is a β-turn antimicrobial peptide. KIKIKPWWWPKIKIK-NH2 can inhibit bacterial biofilm formation and bind to lipopolysaccharid. KIKIKPWWWPKIKIK-NH2 shows wound-healing ability in mice bacteria-infected full-thickness wound models. KIKIKPWWWPKIKIK-NH2 can be used for the research of bacterial infection .
    KIKIKPWWWPKIKIK-NH2
  • HY-P11607
    CyLip-10

    		Bacterial Infection
    CyLip-10 is a microbial-derived cyclic-lipid antimicrobial peptide. CyLip-10 has broad-spectrum antimicrobial efficacy, low hemolytic activity, and excellent stability. CyLip-10 can disrupt membrane integrity, inhibit biofilm formation and induce membrane permeabilization and bacterial cell death. CyLip-10 reduces bacterial load, promotes wound healing, and alleviates inflammatory responses in a mouse Methicillin (HY-121544)-resistant Staphylococcus aureus skin wound infection model. CyLip-10 can be used for the bacterial infection .
    CyLip-10
  • HY-P11582
    CyLip-20

    		Bacterial Infection
    CyLip-20 is a cyclic lipopeptide antimicrobial peptide that targets Gram-positive and Gram-negative bacteria. CyLip-20 exhibits low hemolytic activity and mild in vivo toxicity. CyLip-20 disrupts the integrity of bacterial outer membrane, inner membrane and cytoplasmic membrane by binding to bacterial lipopolysaccharide (LPS), triggering membrane permeabilization, depolarization and leakage of intracellular contents, and inhibits bacterial biofilm formation. In animal models, CyLip-20 reduces the bacterial load in skin wounds of mice infected with MRSA, promotes wound healing, decreases the levels of inflammatory cytokines and reduces inflammatory cell infiltration. CyLip-20 can be used in research related to MRSA skin wound infections .
    CyLip-20
  • HY-184201
    Anti-MRSA agent 44

    		Bacterial Interleukin Related Infection
    Anti-MRSA agent 44 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. Anti-MRSA agent 44 exihibits antibiofilm activity against MRSA. Anti-MRSA agent 44 reduces bacterial counts and biofilm burdens, accelerates wound healing, lowers inflammatory cytokine levels in mouse models. Anti-MRSA agent 44 can be used for the research of MRSA skin wound infection and MRSA catheter-associated biofilm infection .
    Anti-MRSA agent 44
  • HY-183711
    Antibacterial agent 344

    		Bacterial Heme Oxygenase (HO) Infection
    Antibacterial agent 344 is an antibacterial agent with potent biofilm inhibition (IC50 = 0.27 μM). Antibacterial agent 344 inhibits heme oxygenase (HemO), impairs iron homeostasis, virulence factor production, and motility. Antibacterial agent 344 synergizes with Ciprofloxacin (HY-B0356) and Tobramycin (HY-B0441), enhancing their efficacy and delaying the development of resistance. Antibacterial agent 344 improves bacterial-infected Galleria mellonella survival, and reduces bacterial load in mice wounds. Antibacterial agent 344 can be used for the research of Pseudomonas aeruginosa infections .
    Antibacterial agent 344
  • HY-181677
    Antibacterial agent 325

    		Bacterial Reactive Oxygen Species (ROS) Lactate Dehydrogenase Infection
    Antibacterial agent 325 is an antibacterial agent. Antibacterial agent 325 exerts potent broad-spectrum antibacterial activity and shows bactericidal activity. Antibacterial agent induces membrane depolarization, disrupts the membrane integrity, increasess ROS production and lipid peroxidation levels. Antibacterial agent 325 inhibits the metabolic activity and Lactate Dehydrogenase (LDH) activity. Antibacterial agent 325 exhibits low drug resistance development in bacteria, low hemolysis and cytotoxicity. Antibacterial agent 325 can be used for the research of bacterial infection .
    Antibacterial agent 325
  • HY-184287
    Antibacterial agent 352

    		Bacterial Topoisomerase DNA/RNA Synthesis Infection
    Antibacterial agent 352 is an orally active Antibacterial agent. Antibacterial agent 352 binds to the active cavity of Staphylococcus aureus DNA gyrase via hydrogen bonding, π-π stacking and hydrophobic interactions, thereby blocking bacterial DNA synthesis. Antibacterial agent 352 exhibits antibacterial activity against Gram-positive bacteria including Staphylococcus aureus, Bacillus pumilus, Staphylococcus epidermidis and Enterococcus faecalis. Antibacterial agent 352 can disrupt established Staphylococcus aureus biofilms and inhibit the formation of Staphylococcus aureus biofilms. Antibacterial agent 352 can be used in the research of Staphylococcus aureus wound infections .
    Antibacterial agent 352
  • HY-B0614C
    Mafenide propionate

    		Carbonic Anhydrase Bacterial Dihydrofolate reductase (DHFR) Infection
    Mafenide propionate is a dual inhibitor of dihydropteroate synthase (Dihydropteroate synthase) and carbonic anhydrase (Carbonic anhydrase). Mafenide propionate disrupts nucleotide biosynthesis by inhibiting the de novo base synthesis pathway, thereby exerting broad-spectrum antibacterial and cytotoxic effects without inducing mutations. Mafenide propionate can be used for wound assessment and promotes the formation of healthy granulation tissue, making it suitable for scenarios such as mesh skin grafting. Mafenide propionate has been widely used in studies on diseases associated with burn wound infections, acute and chronic wounds, blast injuries, open fractures, and necrotizing fasciitis .
    Mafenide propionate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: